Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.

30 Jun 2010

Response Biomedical signs subscription agreement for C$8 million private placement

Response Biomedical Corporation announced today the signing of a subscription agreement providing for the sale of C$8 million of its common shares to funds affiliated with OrbiMed Advisors, LLC. The closing of the private placement is subject to receipt of all necessary regulatory approvals, including the approval of the Toronto Stock Exchange and the shareholders of the Company.

29 Jun 2010

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.

29 Jun 2010

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

The Associated Press: "Americans increasingly are treated to death, spending more time in hospitals in their final days, trying last-ditch treatments that often buy only weeks of time, and racking up bills that have made medical care a leading cause of bankruptcies. More than 80 percent of people who die in the United States have a long, progressive illness such as cancer, heart failure or Alzheimer's disease."

29 Jun 2010

Pittsburgh companies using wellness to try to keep health costs down

Pittsburgh companies are using wellness incentives in the workplace to trim their health care costs as "small businesses prepare for a lift in their efforts to keep workers healthy, courtesy of health care reform," the Pittsburgh Business Times reports.

28 Jun 2010

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

28 Jun 2010

Florida Hospital Zephyrhills achieves Heart Failure Institute accreditation

The Healthcare Accreditation Colloquium announced today that the Heart Institute at Florida Hospital Zephyrhills has achieved status as the state's first accredited Heart Failure Institute.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Digoxin drug may increase risk of premature death in patients with kidney disease

For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

25 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Hidden heart condition raise stroke and heart failure risk: Report

According to the National Stroke Foundation a hidden and largely undetected heart condition is costing the Australian economy over $1.2 billion a year. In a report released today the Foundation has said that Atrial Fibrillation (AF), commonly manifested as severe irregularity of heart beat and palpitation that may go unnoticed is affecting more than 240,000 Australians at present with half over the age of 75.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

LifeVantage Corporation, the maker of Protandim®, a patented, science-based solution to oxidative stress, announced today that a peer-reviewed manuscript was published in the Journal of Dietary Supplements examining the beneficial effects of Protandim® on a mouse model of Duchenne Muscular Dystrophy (DMD), an X-linked inherited disease affecting one in 3,500 males.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Long-term data presented today from Ardian's SYMPLICITY HTN-1 study demonstrate that the significant reductions in blood pressure achieved using Renal Denervation treatment are sustained through 24 months. The data were presented at the late breaking trials session of the European Society of Hypertension Annual Scientific meeting in Oslo, Norway.

22 Jun 2010

Heart Failure News and Research

Further Reading

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Response Biomedical signs subscription agreement for C$8 million private placement

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Pittsburgh companies using wellness to try to keep health costs down

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Florida Hospital Zephyrhills achieves Heart Failure Institute accreditation

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

Digoxin drug may increase risk of premature death in patients with kidney disease

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Hidden heart condition raise stroke and heart failure risk: Report

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Exercise alone without creatine supplements helps in cardiac rehabilitation

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News